Trials / Completed
CompletedNCT06680102
Probiotic Ameliorates Adult Allergic Rhinitis and Modulates Gut Microbiota
The Effectiveness of Weizmannia Coagulans BC99 in Alleviating Allergic Rhinitis in Adults and Its Impact on the Gut Microbiota.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 78 (actual)
- Sponsor
- Wecare Probiotics Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Assessing the clinical efficacy of weizmannia coagulans BC99 in alleviating allergic rhinitis symptoms, improving gut microbiota, and reducing adverse reactions in patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Probiotic | The experimental phase of this study lasts for 8 weeks, with each patient making three visits at weeks 1, 4, and 8. |
| DIETARY_SUPPLEMENT | Maltodextrin | The experimental phase of this study lasts for 8 weeks, with each patient making three visits at weeks 1, 4, and 8. |
Timeline
- Start date
- 2024-11-25
- Primary completion
- 2024-12-25
- Completion
- 2025-03-25
- First posted
- 2024-11-08
- Last updated
- 2025-07-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06680102. Inclusion in this directory is not an endorsement.